{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:26Z","timestamp":1793146646307,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Science and Technology Fund of Guizhou Provincial Health Commission","award":["gzwkj2024-330"],"award-info":[{"award-number":["gzwkj2024-330"]}]},{"name":"Science and Technology Fund of Guizhou Provincial Health Commission","award":["gzwkj2024-330"],"award-info":[{"award-number":["gzwkj2024-330"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Paliperidone palmitate is a second-generation antipsychotic that has undergone extensive investigation in clinical trials. However, real-world studies assessing its safety in large populations are lacking. As such, this study aimed to comprehensively evaluate real-world adverse drug events (ADEs) linked to paliperidone palmitate by employing data mining techniques on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study retrieved ADE reports from the FAERS database covering the period from 2009 through the third quarter of 2024, and from the JADER database covering the period from 2013 through the second quarter of 2024. Utilizing disproportionality analyses such as the reporting odds ratios (ROR), proportional reporting ratios (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item Poisson shrinkage (MGPS), significant associations between ADEs and paliperidone palmitate were evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 27,672 ADE reports related to paliperidone palmitate were identified in FAERS, with 285 significantly disproportionate preferred terms (PTs) identified by all four algorithms. Paliperidone palmitate-associated ADEs encompassed 27 System Organ Classes (SOCs). The top three PTs with the highest reported cases were off-label use, drug ineffective, and hospitalization. Common ADEs included increased blood prolactin, galactorrhea, and schizophrenia, which was consistent with drug label. Noteworthy, unexpected signals not listed in the drug label were also identified, such as psychosexual disorders, prolactin-producing pituitary tumors, suicide attempt, and sudden death. The median onset time for all ADEs was 40 days. Furthermore, gender-based difference in risk signals was detected. Females are more likely to experience elevated blood prolactin and weight increase, whereas males are more prone to sexual dysfunction. Among the 1,065 ADE reports from the JADER database, we identified 51 positive signals, 35 of which overlapped with those found in FAERS, including schizophrenia, hyperprolactinemia, and erectile dysfunction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The study findings from two independent databases serve as crucial references for ensuring the safe of paliperidone palmitate. Additionally, the gender-specific monitoring references provided can enhance clinical surveillance efforts and facilitate more effective risk identification.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12888-025-06493-0","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T10:52:36Z","timestamp":1737370356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases"],"prefix":"10.1186","volume":"25","author":[{"given":"Siyu","family":"Lou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyong","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"6493_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3389\/fphar.2019.00681","volume":"10","author":"S Agrawal","year":"2019","unstructured":"Agrawal S, Vamadevan P, Mazibuko N, Bannister R, Swery R, Wilson S, Edwards S. A new method for ethical and efficient evidence generation for off-label medication use in Oncology (A Case Study in Glioblastoma). Front Pharmacol. 2019;10:681.","journal-title":"Front Pharmacol"},{"issue":"9","key":"6493_CR2","first-page":"e28771","volume":"14","author":"N Allena","year":"2022","unstructured":"Allena N, Doppalapudi S, Khanal S, Tank S, Nasr R. Acute Dystonia with Rhabdomyolysis Induced by Paliperidone palmitate: a rare adverse effect. Cureus. 2022;14(9):e28771.","journal-title":"Cureus"},{"issue":"10","key":"6493_CR3","first-page":"1086","volume":"28","author":"A Basu","year":"2022","unstructured":"Basu A, Benson C, Turkoz I, Patel C, Baker P, Brown B. Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: a comparative analysis from the Disease Recovery evaluation and modification (DREaM) study. J Manag Care Spec Pharm. 2022;28(10):1086\u201395.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"6493_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"6493_CR5","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","volume":"72","author":"J Berwaerts","year":"2015","unstructured":"Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW. Efficacy and safety of the 3-Month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830\u20139.","journal-title":"JAMA Psychiatry"},{"issue":"16","key":"6493_CR6","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.2165\/0003495-200868160-00002","volume":"68","author":"D Bishara","year":"2008","unstructured":"Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs. 2008;68(16):2269\u201392.","journal-title":"Drugs"},{"issue":"3","key":"6493_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/13651501.2019.1576905","volume":"23","author":"JM Bonete Ll\u00e1cer","year":"2019","unstructured":"Bonete Ll\u00e1cer JM, Mart\u00ednez Hortelano A, Richart Albelda B. Hyperprolactinemia in psychotic patients treated in monotherapy with long-acting injectable antipsychotics. Int J Psychiatry Clin Pract. 2019;23(3):189\u201393.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"9","key":"6493_CR8","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1038\/s41380-023-02175-z","volume":"28","author":"L Boyer","year":"2023","unstructured":"Boyer L, Falissard B, Nuss P, Collin C, Duret S, Rabbani M, De Chefdebien I, Tonelli I, Llorca PM, Fond G. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders. Mol Psychiatry. 2023;28(9):3709\u201316.","journal-title":"Mol Psychiatry"},{"key":"6493_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/NDT.S374696","volume":"19","author":"S Bramante","year":"2023","unstructured":"Bramante S, Di Salvo G, Maina G, Rosso G. Paliperidone palmitate: a breakthrough treatment for Schizophrenia? A review on patient adherence levels, Healthcare Resource Utilization and costs. Neuropsychiatr Dis Treat. 2023;19:519\u201330.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"8","key":"6493_CR10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","volume":"27","author":"EG Brown","year":"2004","unstructured":"Brown EG. Using MedDRA: implications for risk management. Drug Saf. 2004;27(8):591\u2013602.","journal-title":"Drug Saf"},{"issue":"1","key":"6493_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/s12888-021-03513-7","volume":"21","author":"HW Chan","year":"2021","unstructured":"Chan HW, Huang CY, Yen YC. Clinical outcomes of paliperidone long-acting injection in patients with schizophrenia: a 1-year retrospective cohort study. BMC Psychiatry. 2021;21(1):507.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"6493_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11096-022-01395-7","volume":"44","author":"C Chen","year":"2022","unstructured":"Chen C, Zhang C, Jin Z, Wu B, Xu T. Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system. Int J Clin Pharm. 2022;44(3):689\u201397.","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"6493_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/14737175.2024.2325655","volume":"24","author":"G Cirnigliaro","year":"2024","unstructured":"Cirnigliaro G, Battini V, Castiglioni M, Renne M, Mosini G, Cheli S, Carnovale C, Dell\u2019osso B. Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults. Expert Rev Neurother. 2024;24(4):325\u201332.","journal-title":"Expert Rev Neurother"},{"key":"6493_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-244X-12-26","volume":"12","author":"D Coppola","year":"2012","unstructured":"Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, Nuamah I, Sulaiman A, Pandina G. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry. 2012;12:26.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"6493_CR15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41443-023-00717-1","volume":"36","author":"G Corona","year":"2024","unstructured":"Corona G, Rastrelli G, Bianchi N, Sparano C, Sforza A, Vignozzi L, Maggi M. Hyperprolactinemia and male sexual function: focus on erectile dysfunction and sexual desire. Int J Impot Res. 2024;36(4):324\u201332.","journal-title":"Int J Impot Res"},{"issue":"6","key":"6493_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2174\/092986710790416326","volume":"17","author":"A Corsonello","year":"2010","unstructured":"Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17(6):571\u201384.","journal-title":"Curr Med Chem"},{"key":"6493_CR17","doi-asserted-by":"publisher","first-page":"1329409","DOI":"10.3389\/fphar.2024.1329409","volume":"15","author":"Z Cui","year":"2024","unstructured":"Cui Z, Zhai Z, Xie D, Wang L, Cheng F, Lou S, Zou F, Pan R, Chang S, Yao H, She J, Zhang Y, Yang X. From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis. Front Pharmacol. 2024;15:1329409.","journal-title":"Front Pharmacol"},{"issue":"8","key":"6493_CR18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0006-3223(98)00043-2","volume":"44","author":"F Curtin","year":"1998","unstructured":"Curtin F, Schulz P. Multiple correlations and Bonferroni\u2019s correction. Biol Psychiatry. 1998;44(8):775\u20137.","journal-title":"Biol Psychiatry"},{"issue":"9","key":"6493_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2165\/11634500-000000000-00000","volume":"26","author":"M De Hert","year":"2012","unstructured":"De Hert M, Yu W, Detraux J, Sweers K, Van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733\u201359.","journal-title":"CNS Drugs"},{"issue":"6","key":"6493_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"6493_CR21","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.neurobiolaging.2011.05.005","volume":"33","author":"M Ewers","year":"2012","unstructured":"Ewers M, Schmitz S, Hansson O, Walsh C, Fitzpatrick A, Bennett D, Minthon L, Trojanowski JQ, Shaw LM, Faluyi YO, Vellas B, Dubois B, Blennow K, Buerger K, Teipel SJ, Weiner M, Hampel H. Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer\u2019s disease. Neurobiol Aging. 2012;33(8):1599\u2013608.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"6493_CR22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s12325-019-01201-3","volume":"37","author":"A Farkouh","year":"2020","unstructured":"Farkouh A, Riedl T, Gottardi R, Czejka M, Kautzky-Willer A. Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature. Adv Ther. 2020;37(2):644\u201355.","journal-title":"Adv Ther"},{"issue":"2","key":"6493_CR23","first-page":"66","volume":"43","author":"JG Fern\u00e1ndez-Macho","year":"2015","unstructured":"Fern\u00e1ndez-Macho JG, Esp\u00e1rrago-Llorca G, Morales-G\u00f3mez GR, Guisado-Mac\u00edas JA. Paliperidone-induced rhabdomyolysis: a case report. Actas Esp De Psiquiatria. 2015a;43(2):66\u20138.","journal-title":"Actas Esp De Psiquiatria"},{"issue":"2","key":"6493_CR24","first-page":"132","volume":"117","author":"Y Fujii","year":"2015","unstructured":"Fujii Y. [What lessons should we learn from the death of patients on Xeplion?]. Seishin Shinkeigaku Zasshi. 2015;117(2):132\u201345.","journal-title":"Seishin Shinkeigaku Zasshi"},{"issue":"9","key":"6493_CR25","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40263-017-0437-9","volume":"31","author":"S Gopal","year":"2017","unstructured":"Gopal S, Lane R, Nuamah I, Copenhaver M, Singh J, Hough D, Bach M, Savitz A. Evaluation of potentially prolactin-related adverse events and sexual maturation in adolescents with Schizophrenia treated with Paliperidone extended-release (ER) for 2 years: a Post Hoc Analysis of an open-label Multicenter Study. CNS Drugs. 2017;31(9):797\u2013808.","journal-title":"CNS Drugs"},{"issue":"4","key":"6493_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","volume":"4","author":"C Hjorth\u00f8j","year":"2017","unstructured":"Hjorth\u00f8j C, St\u00fcrup AE, Mcgrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295\u2013301.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"6493_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12916-021-02062-w","volume":"19","author":"A Hodkinson","year":"2021","unstructured":"Hodkinson A, Heneghan C, Mahtani KR, Kontopantelis E, Panagioti M. Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports. BMC Med. 2021;19(1):195.","journal-title":"BMC Med"},{"issue":"3","key":"6493_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.coph.2012.04.002","volume":"12","author":"M Hohenegger","year":"2012","unstructured":"Hohenegger M. Drug induced rhabdomyolysis. Curr Opin Pharmacol. 2012;12(3):335\u20139.","journal-title":"Curr Opin Pharmacol"},{"issue":"10202","key":"6493_CR29","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, B\u00e4ckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351.","journal-title":"Lancet"},{"issue":"1","key":"6493_CR30","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1038\/s41598-022-06611-y","volume":"12","author":"T Imai","year":"2022","unstructured":"Imai T, Hazama K, Kosuge Y, Suzuki S, Ootsuka S. Preventive effect of rebamipide on NSAID-induced lower gastrointestinal tract injury using FAERS and JADER. Sci Rep. 2022;12(1):2631.","journal-title":"Sci Rep"},{"key":"6493_CR31","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3389\/fphar.2019.00874","volume":"10","author":"I Inaba","year":"2019","unstructured":"Inaba I, Kondo Y, Iwasaki S, Tsuruhashi S, Akaishi A, Morita K, Oniki K, Saruwatari J, Ishitsuka Y, Irie T. Risk evaluation for acute kidney Injury Induced by the concomitant use of Valacyclovir, Analgesics, and renin-angiotensin system inhibitors: the detection of signals of drug-drug interactions. Front Pharmacol. 2019;10:874.","journal-title":"Front Pharmacol"},{"issue":"10323","key":"6493_CR32","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","volume":"399","author":"S Jauhar","year":"2022","unstructured":"Jauhar S, Johnstone M, Mckenna PJ. Schizophrenia Lancet. 2022;399(10323):473\u201386.","journal-title":"Schizophrenia Lancet"},{"key":"6493_CR33","doi-asserted-by":"publisher","first-page":"803706","DOI":"10.3389\/fphar.2022.803706","volume":"13","author":"K Kato","year":"2022","unstructured":"Kato K, Mizuno T, Koseki T, Ito Y, Takahashi K, Tsuboi N, Yamada S. Frequency of Immune Checkpoint inhibitor-Induced vasculitides: an observational study using data from the Japanese adverse drug Event Report Database. Front Pharmacol. 2022;13:803706.","journal-title":"Front Pharmacol"},{"issue":"1","key":"6493_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","volume":"45","author":"S Kinoshita","year":"2020","unstructured":"Kinoshita S, Hosomi K, Yokoyama S, Takada M. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. J Clin Pharm Ther. 2020;45(1):65\u201371.","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"6493_CR35","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1093\/schbul\/sbw043","volume":"42","author":"T Kishi","year":"2016","unstructured":"Kishi T, Matsunaga S, Iwata N. Mortality risk Associated with Long-acting Injectable antipsychotics: a systematic review and Meta-analyses of Randomized controlled trials. Schizophr Bull. 2016;42(6):1438\u201345.","journal-title":"Schizophr Bull"},{"issue":"2","key":"6493_CR36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s40211-020-00377-3","volume":"35","author":"B Klein","year":"2021","unstructured":"Klein B, Silberbauer C. [Rhabdomyolysis induced by paliperidone palmitate]. Neuropsychiatr. 2021;35(2):98\u2013101.","journal-title":"Neuropsychiatr"},{"issue":"11","key":"6493_CR37","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamapsychiatry.2023.2696","volume":"80","author":"T Korchia","year":"2023","unstructured":"Korchia T, Achour V, Faugere M, Albeash A, Yon DK, Boyer L, Fond G. Sexual dysfunction in Schizophrenia: a systematic review and Meta-analysis. JAMA Psychiatry. 2023;80(11):1110\u201320.","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"6493_CR38","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/pds.964","volume":"13","author":"K Kubota","year":"2004","unstructured":"Kubota K, Koide D, Hirai T. Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol Drug Saf. 2004;13(6):387\u201394.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6493_CR39","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-clinpsy-032813-153657","volume":"10","author":"TM Laursen","year":"2014","unstructured":"Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425\u201348.","journal-title":"Annu Rev Clin Psychol"},{"issue":"8","key":"6493_CR40","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40263-023-01028-1","volume":"37","author":"Q Li","year":"2023","unstructured":"Li Q, Li X, Ye C, Jia M, Si T. Effectiveness and safety of switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M) in the management of Schizophrenia: a systematic review and Meta-analysis. CNS Drugs. 2023;37(8):695\u2013713.","journal-title":"CNS Drugs"},{"issue":"1","key":"6493_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40263-023-01056-x","volume":"38","author":"X Li","year":"2024","unstructured":"Li X, Ye C, Zhang W, Jia M, Wang G. Factors Associated with Symptom stabilization that allow for successful transition from once-monthly paliperidone palmitate to three-monthly paliperidone palmitate: a Post Hoc Analysis examined clinical characteristics in Chinese patients with Schizophrenia. CNS Drugs. 2024;38(1):55\u201365.","journal-title":"CNS Drugs"},{"key":"6493_CR42","doi-asserted-by":"publisher","first-page":"1485190","DOI":"10.3389\/fphar.2024.1485190","volume":"15","author":"Q Liu","year":"2024","unstructured":"Liu Q, Cui Z, Deng C, Yang C, Shi T. A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases. Front Pharmacol. 2024;15:1485190.","journal-title":"Front Pharmacol"},{"issue":"Suppl 1Suppl 1","key":"6493_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/cns.13375","volume":"27","author":"WA Lo","year":"2021","unstructured":"Lo WA, Ki-Yan Mak D, Ming-Cheuk Wong M, Chan OW, Mo-Ching Chui E, Wai-Sau Chung D, Suk-Han Ip G, Lau KS, Lee CK, Mui J, Tam KL, Tse S, Wong KL. Achieving better outcomes for schizophrenia patients in Hong Kong: strategies for improving treatment adherence. CNS Neurosci Ther. 2021;27(Suppl 1Suppl 1):12\u20139.","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"6493_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3371\/CSRP.MALA.123015","volume":"12","author":"R Madan","year":"2018","unstructured":"Madan R, Langenfeld RJ, Ramaswamy S. Paliperidone palmitate-Induced Retrograde Ejaculation. Clin Schizophr Relat Psychos. 2018;12(2):86\u20138.","journal-title":"Clin Schizophr Relat Psychos"},{"key":"6493_CR45","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.2147\/NDT.S175364","volume":"14","author":"M Mathews","year":"2018","unstructured":"Mathews M, Nuamah I, Savitz AJ, Hough DW, Najarian D, Kim E, Gopal S. Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. Neuropsychiatr Dis Treat. 2018;14:2807\u201316.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"6493_CR46","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40263-019-00631-5","volume":"33","author":"F Mazhar","year":"2019","unstructured":"Mazhar F, Pozzi M, Gentili M, Scatigna M, Clementi E, Radice S, Carnovale C. Association of Hyponatraemia and antidepressant drugs: a Pharmacovigilance-Pharmacodynamic Assessment through an analysis of the US Food and Drug Administration adverse event reporting system (FAERS) database. CNS Drugs. 2019;33(6):581\u201392.","journal-title":"CNS Drugs"},{"issue":"9","key":"6493_CR47","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","volume":"21","author":"F Mazhar","year":"2021","unstructured":"Mazhar F, Battini V, Gringeri M, Pozzi M, Mosini G, Marran AM, N, Akram S, Van Manen RP, Radice S, Clementi E, Carnovale C. The impact of anti-TNF\u03b1 agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database. Expert Opin Biol Ther. 2021;21(9):1281\u201390.","journal-title":"Expert Opin Biol Ther"},{"issue":"19","key":"6493_CR48","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1001\/jama.2014.4310","volume":"311","author":"JP Mcevoy","year":"2014","unstructured":"Mcevoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA. 2014;311(19):1978\u201387.","journal-title":"JAMA"},{"key":"6493_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","volume":"30","author":"J Mcgrath","year":"2008","unstructured":"Mcgrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67\u201376.","journal-title":"Epidemiol Rev"},{"issue":"2","key":"6493_CR50","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/jcm10020308","volume":"10","author":"AL Montejo","year":"2021","unstructured":"Montejo AL, De Alarc\u00f3n R, Prieto N, Acosta JM, Buch B, Montejo L. Management strategies for antipsychotic-related sexual dysfunction: a clinical approach. J Clin Med. 2021;10(2):308.","journal-title":"J Clin Med"},{"issue":"4","key":"6493_CR51","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1248\/yakushi.15-00224-5","volume":"136","author":"M Nakamura","year":"2016","unstructured":"Nakamura M. [Analysis of spontaneously reported adverse events]. Yakugaku Zasshi. 2016;136(4):549\u201356.","journal-title":"Yakugaku Zasshi"},{"key":"6493_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16036","volume-title":"Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: A case report","author":"M Nersesjan","year":"2024","unstructured":"Nersesjan M, Wagner M, Dalhoff KP, Petersen TS, B\u00f8gevig S, Horwitz H. Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: a case report. Br J Clin Pharmacol; 2024."},{"key":"6493_CR53","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.2147\/DDDT.S81998","volume":"9","author":"K Nomura","year":"2015","unstructured":"Nomura K, Takahashi K, Hinomura Y, Kawaguchi G, Matsushita Y, Marui H, Anzai T, Hashiguchi M, Mochizuki M. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. Drug Des Devel Ther. 2015;9:3031\u201341.","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"6493_CR54","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1176\/appi.ajp.2020.20071120","volume":"178","author":"G Ostuzzi","year":"2021","unstructured":"Ostuzzi G, Bertolini F, Del Giovane C, Tedeschi F, Bovo C, Gastaldon C, Nos\u00e9 M, Ogheri F, Papola D, Purgato M, Turrini G, Correll CU, Barbui C. Maintenance treatment with Long-Acting Injectable antipsychotics for people with nonaffective psychoses: A Network Meta-Analysis. Am J Psychiatry. 2021;178(5):424\u201336.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"6493_CR55","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40263-022-00976-4","volume":"37","author":"S Pappa","year":"2023","unstructured":"Pappa S, Barnett J, Mason K. A 10-Year observational study of the Use, acceptability and effectiveness of long-acting paliperidone palmitate: implications for clinical decision making. CNS Drugs. 2023;37(1):107\u201316.","journal-title":"CNS Drugs"},{"issue":"5","key":"6493_CR56","first-page":"421","volume":"28","author":"J Peuskens","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421\u201353.","journal-title":"CNS Drugs"},{"issue":"1","key":"6493_CR57","first-page":"37","volume":"54","author":"F Rad","year":"2019","unstructured":"Rad F, Buica AM, Anghel GC, Stancu M, Dobrescu I. Hormonal imbalance and pituitary adenoma during antipsychotic treatment in an adolescent with bipolar affective disorder. Riv Psichiatr. 2019;54(1):37\u20139.","journal-title":"Riv Psichiatr"},{"key":"6493_CR58","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pnpbp.2014.02.007","volume":"53","author":"Q Rui","year":"2014","unstructured":"Rui Q, Wang Y, Liang S, Liu Y, Wu Y, Wu Q, Nuamah I, Gopal S. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;53:45\u201353.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10","key":"6493_CR59","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36(10):995.","journal-title":"Drug Saf"},{"issue":"7","key":"6493_CR60","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1089\/cap.2014.0130","volume":"25","author":"A Savitz","year":"2015","unstructured":"Savitz A, Lane R, Nuamah I, Singh J, Hough D, Gopal S. Long-term safety of Paliperidone Extended Release in adolescents with Schizophrenia: an Open-Label, flexible dose study. J Child Adolesc Psychopharmacol. 2015;25(7):548\u201357.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"6493_CR61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/ijnp\/pyw018","volume":"19","author":"AJ Savitz","year":"2016","unstructured":"Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Janik A, Schotte A, Hough D, Fleischhacker WW. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind. Noninferiority Study Int J Neuropsychopharmacol. 2016;19(7):19.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"6493_CR62","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/17512433.2022.2020641","volume":"15","author":"G Schoretsanitis","year":"2022","unstructured":"Schoretsanitis G, Haen E, Piacentino D, Conca A, Endres K, Hiemke C, Gr\u00fcnder G, Paulzen M. Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitate. Expert Rev Clin Pharmacol. 2022;15(2):243\u20139.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"6493_CR63","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1192\/bjp.2021.61","volume":"220","author":"D Siskind","year":"2022","unstructured":"Siskind D, Orr S, Sinha S, Yu O, Brijball B, Warren N, Maccabe JH, Smart SE, Kisely S. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. 2022;220(3):115\u201320.","journal-title":"Br J Psychiatry"},{"issue":"12","key":"6493_CR64","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","volume":"28","author":"M Solmi","year":"2023","unstructured":"Solmi M, Seitidis G, Mavridis D, Correll CU, Dragioti E, Guimond S, Tuominen L, Darg\u00e9l A, Carvalho AF, Fornaro M, Maes M, Monaco F, Song M, Il Shin J, Cortese S. Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the global burden of Disease (GBD) 2019. Mol Psychiatry. 2023;28(12):5319\u201327.","journal-title":"Mol Psychiatry"},{"issue":"9","key":"6493_CR65","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jaac.2023.05.003","volume":"62","author":"JR Strawn","year":"2023","unstructured":"Strawn JR, Geracioti TD. Editorial: a better perspective on antipsychotic-related hyperprolactinemia in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2023;62(9):967\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"6493_CR66","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/wps.20567","volume":"17","author":"TS Stroup","year":"2018","unstructured":"Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341\u201356.","journal-title":"World Psychiatry"},{"issue":"1","key":"6493_CR67","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/hup.1258","volume":"27","author":"Y Suzuki","year":"2012","unstructured":"Suzuki Y, Fukui N, Watanabe J, Ono S, Sugai T, Tsuneyama N, Saito M, Inoue Y, Someya T. QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone. Human Psychopharmacol. 2012;27(1):39\u201342.","journal-title":"Human Psychopharmacol"},{"issue":"5","key":"6493_CR68","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00228-017-2407-z","volume":"74","author":"K Svendsen","year":"2018","unstructured":"Svendsen K, Wood M, Olsson E, Nordeng H. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase\u00ae. Eur J Clin Pharmacol. 2018;74(5):627\u201336.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"6493_CR69","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/acps.12913","volume":"138","author":"A Tanskanen","year":"2018","unstructured":"Tanskanen A, Tiihonen J, Taipale H. Mortality in schizophrenia: 30-year nationwide follow-up study. Acta Psychiatr Scand. 2018;138(6):492\u20139.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"6493_CR70","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/npr2.12190","volume":"41","author":"M Tasaki","year":"2021","unstructured":"Tasaki M, Yasui-Furukori N, Yokoyama S, Shinozaki M, Sugawara N, Shimoda K. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. Neuropsychopharmacol Rep. 2021;41(3):379\u201384.","journal-title":"Neuropsychopharmacol Rep"},{"issue":"4","key":"6493_CR71","doi-asserted-by":"publisher","first-page":"185","DOI":"10.9740\/mhc.2016.07.185","volume":"6","author":"A Tewksbury","year":"2016","unstructured":"Tewksbury A, Olander A. Management of antipsychotic-induced hyperprolactinemia. Ment Health Clin. 2016;6(4):185\u201390.","journal-title":"Ment Health Clin"},{"issue":"6","key":"6493_CR72","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/FJC.0b013e318217d941","volume":"57","author":"P Vigneault","year":"2011","unstructured":"Vigneault P, Kaddar N, Bourgault S, Caillier B, Pilote S, Patoine D, Simard C, Drolet B. Prolongation of cardiac ventricular repolarization under paliperidone: how and how much? J Cardiovasc Pharmacol. 2011;57(6):690\u20135.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"6493_CR73","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/schbul\/sbad089","volume":"50","author":"D Wang","year":"2024","unstructured":"Wang D, Schneider-Thoma J, Siafis S, Burschinski A, Dong S, Wu H, Zhu Y, Davis JM, Priller J, Leucht S. Long-acting Injectable Second-Generation antipsychotics vs Placebo and their oral formulations in Acute Schizophrenia: a systematic review and Meta-analysis of randomized-controlled-trials. Schizophr Bull. 2024;50(1):132\u201344.","journal-title":"Schizophr Bull"},{"issue":"3","key":"6493_CR74","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17460441.2020.1682994","volume":"15","author":"A Weso\u0142owska","year":"2020","unstructured":"Weso\u0142owska A, Jastrz\u0119bska-Wi\u0119sek M, Cios A, Partyka A. The preclinical discovery and development of paliperidone for the treatment of schizophrenia. Expert Opin Drug Discov. 2020;15(3):279\u201392.","journal-title":"Expert Opin Drug Discov"},{"issue":"3","key":"6493_CR75","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S2215-0366(23)00005-6","volume":"10","author":"I Winter-Van Rossum","year":"2023","unstructured":"Winter-Van Rossum I, Weiser M, Galderisi S, Leucht S, Bitter I, Glenth\u00f8j B, Hasan A, Luykx J, Kupchik M, Psota G, Rocca P, Stefanis N, Teitelbaum A, Bar Haim M, Leucht C, Kemmler G, Schurr T, Davidson M, Kahn RS, Fleischhacker WW. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). Lancet Psychiatry. 2023;10(3):197\u2013208.","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"6493_CR76","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1248\/bpb.b22-00497","volume":"45","author":"B Xue","year":"2022","unstructured":"Xue B, Ishiwata Y, Kawano Y, Takahashi H, Negishi K, Aoyama T, Nagata M. Paliperidone-Induced Acute Hyperglycemia is caused by adrenaline secretion via the activation of hypothalamic AMP-Activated protein kinase. Biol Pharm Bull. 2022;45(11):1669\u201377.","journal-title":"Biol Pharm Bull"},{"key":"6493_CR77","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","volume":"347","author":"H Zhu","year":"2024","unstructured":"Zhu H, Qu Y, Du Z, Zhou Q, Shen Y, Jiang Y, Zhou Z, Zhou H. Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database. J Affect Disord. 2024;347:45\u201350.","journal-title":"J Affect Disord"},{"key":"6493_CR78","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","volume":"15","author":"F Zou","year":"2024","unstructured":"Zou F, Cui Z, Lou S, Ou Y, Zhu C, Shu C, Chen J, Zhao R, Wu Z, Wang L, Chen Z, Chen H, Lan Y. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol. 2024a;15:1338902.","journal-title":"Front Pharmacol"},{"key":"6493_CR79","doi-asserted-by":"publisher","first-page":"1392914","DOI":"10.3389\/fphar.2024.1392914","volume":"15","author":"S Zou","year":"2024","unstructured":"Zou S, Ouyang M, Zhao Y, Cheng Q, Shi X, Sun M. A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases. Front Pharmacol. 2024b;15:1392914.","journal-title":"Front Pharmacol"},{"issue":"1","key":"6493_CR80","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","volume":"11","author":"I Zucker","year":"2020","unstructured":"Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biology Sex Differences. 2020;11(1):32.","journal-title":"Biology Sex Differences"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06493-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-06493-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06493-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T10:52:42Z","timestamp":1737370362000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-06493-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6493"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-06493-0","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"11 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets were extracted from the public available FAERS and JADER databases, the ethics approval and consent to participate is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}